Why OraSure Technologies (OSUR) Is Back in the Spotlight as Sale Pressure Builds

OraSure Technologies, Inc. (NASDAQ:OSUR) is one of the 10 potential takeover targets with strong price momentum. On March 17, 2026, Reuters reported that activist investor Altai Capital Management pushed the company to explore a sale, arguing that OraSure could fetch roughly double its current share price. Altai also pressed for board seats after nominating directors, escalating a campaign to force strategic change.

That pressure builds on an already active takeover backdrop. Reuters had earlier reported that healthcare entrepreneur Ron Zwanziger made an acquisition approach in 2025, which the company rejected, and later warned of a more adversarial path. The combination of a prior rejected bid and an ongoing activist campaign makes OraSure a live strategic situation rather than a speculative one.

Likoper/Shutterstock.com

The stock’s momentum reflects that shift. Shares were up about 35% year-to-date as of April 14 close, with insider buying also reported during that period, suggesting improving investor sentiment alongside the takeover narrative.

Fundamentally, OraSure operates in diagnostics and sample management, including infectious disease testing and molecular collection tools, areas that can attract strategic buyers looking to expand capabilities. The company said in mid-March that it is approaching a series of regulatory and commercial milestones, positioning itself at what it described as an “inflection point” even as activist pressure intensifies.

OraSure Technologies, Inc. (NASDAQ:OSUR) develops diagnostic tests and sample collection solutions for infectious diseases and other healthcare applications.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.